Antibody Drug Conjugates
Advanced Linker & Conjugation Technologies for Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) combine the targeting specificity of monoclonal antibodies with the potent cytotoxic activity of small-molecule payloads, enabling selective destruction of diseased cells while minimizing systemic toxicity. The performance of ADCs depends heavily on linker stability, conjugation precision, payload release control, and overall molecular homogeneity. Advanced linker chemistry and bioconjugation technologies are therefore essential for the development of safe, stable, and effective ADC therapeutics.
BIOMATRIK provides a comprehensive portfolio of ADC linker technologies, PEGylated conjugation reagents, and site-specific bioconjugation tools engineered for antibody modification, payload attachment, and next-generation targeted therapeutics.
| Application Area | Key Products | Primary Benefits |
|---|---|---|
| Site-Specific Antibody Conjugation | Maleimide Linkers, Dibromo-Maleimides, Bis-Sulfone Linkers | Controlled drug-to-antibody ratio; Improved conjugate homogeneity |
| Cleavable ADC Linkers | Disulfide Linkers, Acid-Cleavable Linkers, Enzyme-Cleavable PEG Linkers | Controlled intracellular payload release |
| Stable Non-Cleavable Linkers | PEGylated Maleimides, NHS Ester Linkers | Enhanced plasma stability; Reduced premature drug release |
| Bioorthogonal ADC Assembly | DBCO-PEG, Azide-PEG, Clickable Linkers | Rapid and selective conjugation under mild conditions |
| PEGylated ADC Optimization | PEG Linkers, Heterobifunctional PEG Reagents | Improved solubility; Reduced aggregation and immunogenicity |
Site-Specific Conjugation for Homogeneous ADCs
Precise conjugation strategies are critical for controlling drug-to-antibody ratio (DAR), preserving antibody activity, and improving therapeutic consistency. BIOMATRIK supplies cysteine-reactive maleimides, dibromo-maleimides, and bis-sulfone linkers optimized for site-selective antibody modification and stable thioether bond formation.
Key products: Maleimide-PEG-NHS, Dibromo-Maleimide Linkers, Bis-Sulfone PEG Linkers, Thiol-Reactive PEGs
Cleavable Linkers for Controlled Payload Release
Cleavable ADC linkers are engineered to release cytotoxic payloads selectively within target cells in response to intracellular triggers such as pH, redox conditions, or enzymatic activity. These systems improve therapeutic precision while minimizing systemic exposure to free payloads.
Key products: Disulfide PEG Linkers, Acid-Labile Linkers, Enzyme-Cleavable PEG Linkers
PEGylation Technologies for ADC Optimization
PEGylation enhances ADC stability, solubility, and pharmacokinetic performance while reducing aggregation and non-specific interactions. BIOMATRIK offers monodisperse PEG linkers and heterobifunctional PEG reagents designed to optimize linker flexibility, improve formulation stability, and support advanced ADC architectures.
Key products: PEG-Maleimide, PEG-NHS Esters, Heterobifunctional PEG Linkers, PEGylated Payload Linkers
Click Chemistry for Modular ADC Assembly
Bioorthogonal click chemistry enables rapid and highly selective conjugation under mild conditions, supporting modular ADC assembly and multifunctional therapeutic design. Clickable PEG reagents facilitate efficient attachment of payloads, imaging agents, and targeting ligands while maintaining antibody integrity.
Key products: DBCO-PEG, Azide-PEG, Alkyne-PEG Linkers, Clickable PEG Reagents
Why Choose BIOMATRIK?
High Purity Linker Technologies
Improved reproducibility and minimized free payload contamination
Broad ADC Reagent Portfolio
Comprehensive selection of cleavable and non-cleavable linkers
Site-Specific Conjugation Expertise
Support for homogeneous ADC development and controlled DAR
Custom Linker Design
Tailored PEG lengths, reactive groups, and release mechanisms
Technical & Application Support
Guidance for conjugation optimization, linker selection, and ADC formulation
Explore Our ADC Solutions
From site-specific antibody conjugation and cleavable linker technologies to PEGylated payload delivery and bioorthogonal assembly strategies, BIOMATRIK’s advanced conjugation platforms support the next generation of antibody-drug conjugates. Contact our technical team to discuss customized ADC linker solutions and application-specific bioconjugation strategies for your research and development programs.
Got Questions? Get Answers Now!
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip .